Alpha 2.0
Login Register
» Authors » Esperanza Munoz-Muela

Esperanza Munoz-Muela

Explore the profile of Esperanza Munoz-Muela including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 170
Followers 0
Related Specialties
General Medicine
Infectious Diseases
Allergy & Immunology
Top 10 Co-Authors
Maria Trujillo-Rodriguez
Alicia Gutierrez-Valencia
Ana Serna-Gallego
Luis F Lopez-Cortes
Ezequiel Ruiz-Mateos
Nuria Espinosa
Abraham Saborido-Alconchel
Eva Poveda
Carmen Gasca-Capote
Juan Manuel Praena-Fernandez
Published In
Front Immunol
AIDS
PLoS One
Clin Cancer Res
Microorganisms
Affiliations
Soon will be listed here.
Recent Articles
1.
Correction: Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients
Trujillo-Rodriguez M, Munoz-Muela E, Serna-Gallego A, Praena-Fernandez J, Perez-Gomez A, Gasca-Capote C, et al.
PLoS One . 2024 Nov; 19(11):e0314574. PMID: 39570969
[This corrects the article DOI: 10.1371/journal.pone.0269875.].
2.
Plasma concentrations of IL-6, MIP-1β, IP-10, and PTX-3 as predictors of the immunological response to antiretroviral treatment in people with HIV
Mejias-Trueba M, Saborido-Alconchel A, Serna-Gallego A, Trujillo-Rodriguez M, Munoz-Muela E, Llaves-Flores S, et al.
Front Immunol . 2024 Sep; 15:1447926. PMID: 39267754
Despite effective antiretroviral therapy (ART), 15-30% of people with HIV experience poor CD4 T-cell recovery, termed immunologic non-responders (INR). This study aims to evaluate whether pre-ART plasma levels of interleukin-6...
3.
HIV-1-DNA/RNA and immunometabolism in monocytes: contribution to the chronic immune activation and inflammation in people with HIV-1
Munoz-Muela E, Trujillo-Rodriguez M, Serna-Gallego A, Saborido-Alconchel A, Gasca-Capote C, Alvarez-Rios A, et al.
EBioMedicine . 2024 Sep; 108:105338. PMID: 39265504
Background: Among people living with HIV-1 (PHIV), immunological non-responders (INR) experience incomplete immune recovery despite suppressive antiretroviral treatment (ART), facing more severe non-AIDS events than immunological responders (IR) due to...
4.
Long-term effects on immunological, inflammatory markers, and HIV-1 reservoir after switching to a two-drug versus maintaining a three-drug regimen based on integrase inhibitors
Saborido-Alconchel A, Serna-Gallego A, Trujillo-Rodriguez M, Munoz-Muela E, Alvarez-Rios A, Lozano C, et al.
Front Immunol . 2024 Jul; 15:1423734. PMID: 39055703
Objective: To compare the long-term effects on immune parameters, inflammation, and HIV-1 reservoir after switching to a two-drug (2DR) versus maintaining an integrase inhibitor (InSTI)-based three-drug regimen (3DR). Methods: Cross-sectional...
5.
HIV-1-specific T-cell responses and exhaustion profiles in people with HIV after switching to dual therapy vs. maintaining triple therapy based on integrase inhibitors
Munoz-Muela E, Trujillo-Rodriguez M, Serna-Gallego A, Saborido-Alconchel A, Ruiz-Mateos E, Lopez-Cortes L, et al.
Biomed Pharmacother . 2023 Oct; 168:115750. PMID: 37871555
Background: Dual therapy (DT) has shown comparable results to triple therapy (TT) in efficacy and other immunological aspects. However, there are still some concerns about DT, including several immunological features....
6.
Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV
Saborido-Alconchel A, Serna-Gallego A, Lopez-Cortes L, Trujillo-Rodriguez M, Praena-Fernandez J, Dominguez-Macias M, et al.
J Antimicrob Chemother . 2023 Aug; 78(9):2354-2360. PMID: 37545387
Background: This was a substudy of a Phase IV, randomized clinical trial (ClinicalTrials.gov identifier: NCT04295460) aiming to compare the activity of dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabine (DTG + TAF/FTC)...
7.
Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered
Lopez-Cortes L, Saborido-Alconchel A, Trujillo-Rodriguez M, Serna-Gallego A, Llaves-Flores S, Munoz-Muela E, et al.
Front Immunol . 2023 Apr; 14:1129753. PMID: 37006309
Background: Data on SARS-CoV-2 mRNA vaccine immunogenicity in people living with human immunodeficiency virus (PLWH) and discordant immune response (DIR) are currently limited. Therefore, we compare the immunogenicity of these...
8.
Response to: Reply to: Anti-CD4 autoantibodies in immunological nonresponder people living with HIV: cause of CD4+ T cell depletion?
Munoz-Muela E, Ruiz-Mateos E, Gutierrez-Valencia A, Lopez-Cortes L
AIDS . 2023 Jan; 37(3):554-555. PMID: 36695368
No abstract available.
9.
Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients
Trujillo-Rodriguez M, Munoz-Muela E, Serna-Gallego A, Praena-Fernandez J, Perez-Gomez A, Gasca-Capote C, et al.
PLoS One . 2022 Jul; 17(7):e0269875. PMID: 35834501
Background: The SARS-CoV-2 pandemic has overwhelmed hospital services due to the rapid transmission of the virus and its severity in a high percentage of cases. Having tools to predict which...
10.
Anti-CD4 autoantibodies in immunological nonresponder people with HIV: cause of CD4 + T-cell depletion?
Munoz-Muela E, Trujillo-Rodriguez M, Serna-Gallego A, Ruiz-Mateos E, Espinosa N, Roca-Oporto C, et al.
AIDS . 2022 May; 36(9):1207-1214. PMID: 35608119
Objective: We aimed to evaluate the anti-CD4 IgG role in the poor immune recovery of immunological nonresponder people with HIV (INR). Design: INR display low CD4 + T-cell increase despite...